JANX News and Press, Janux Therapeutics Inc.

The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board me...

2024-07-10 14:06:41 ET Summary Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after o...

2024-07-09 07:00:00 ET Summary Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation...

2024-07-01 11:13:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s note: “Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’ “ was previously published in May 2024. It has since been updated...

2024-06-26 08:32:44 ET Summary Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer drug candidates that activate T cells in the tumor...

2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...

2024-06-12 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-30 13:30:05 ET Wedbush analyst issues SECTOR PERFORM recommendation for JANX on May 30, 2024 11:01AM ET. The previous analyst recommendation was Sector Perform. JANX was trading at $50.07 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-05-30 13:30:05 ET Scotiabank analyst issues UNDERPERFORM recommendation for JANX on May 30, 2024 11:01AM ET. The previous analyst recommendation was Underperform. JANX was trading at $50.07 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2024-05-22 03:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...